Big pharma firms have paused nearly £2bn in UK investments this year | Pharmaceuticals industry

Large pharmaceutical companies have abandoned or interrupted nearly 2 billion pounds in investment in investments in the United Kingdom so far this year, which has made “suffering” to patients, while ministers are preparing for discussions with Donald Trump in the midst of drug pricing.

The government plan for the life science sector, a key pillar of the economy, was disorder, after the shock announcement of the American drug manufacturer last Wednesday, that it would eliminate its London research center of 1 billion pounds Sterling. Two days later, Astrazeneca decided to stop a planned expansion of 200 million pounds sterling in his research facilities in Cambridge.

Combined with a project brought to the Rebut of Astrazeneca in Liverpool and an Eli Lilly laboratory in London, four projects worth more than 1.7 billion pounds Sterling were removed or arrested this year. In total, decisions of more than 13 major projects or companies have damaged the UK’s pharmaceutical industry since 2022, including also site closings and stock market fractions.

Pharmaceutical companies have accused the government not to spend enough drugs enough, arguing that there is little incitement to develop drugs and test them in a country that does not appreciate innovation enough.

Other complaints are expected when deputies in the Sciences, Innovation and Technology Committee question the United Kingdom of MSD and the Director General of Ireland, Ben Lucas, on his decision on Tuesday afternoon.

He will appear alongside the president of Astrazeneca Uk Tom Keith-Roach, Association of the British Pharmaceutical Industry PDG, Richard Torbett and representatives of the government, including the Minister of Sciences Lord Vallance, a former manager of the GSK.

The United States Ambassador to the United Kingdom, Warren Stephens, asked the Chancellor, Rachel Reeves, recently offering pharmaceutical companies on prices when the two met at a private dinner in London, the Financial Times reported. The intervention came before Trump’s visit to the United Kingdom this week. The American president criticized the foreign nations for “freeloading on American innovation”. Medication prices are much higher in the United States and companies have been accused of “gouging” in the past.

Meanwhile, Guy Oliver, the British chief of the American drug manufacturer Bristol Myers Squibb, told Times that because of the “chronic under-investment” in drugs, the American drug manufacturer had canceled 34 partnerships with the NHS in the past year. “There is a human cost for all of this. Patients really have suffered and have been suffering for many years now,” he said.

The manufacturers of drugs have become more vocal on the shortcomings of the United Kingdom since several months negotiations about drug prices broke at the end of August, when the health secretary, Wes Street, gave companies an ultimatum on his last “generous” offer – but was rejected.

This means that the voluntary regime for prices, access and growth of brand medicines, under which pharmaceutical companies reimburse part of their British income at the NHS, continue at a rate that says that the industry is “unsustainable”. The minimum recovery rate of 23.5% for new drugs is much higher than payment rates in other European countries.

MSD, known as Merck in the United States, said that it interrupts all research and development activities in the United Kingdom, which means that 125 scientists based at the Francis Crick Institute and London Bioscience Innovation Center will lose their jobs.

Last week, American drug manufacturer Eli Lilly also said that her London Gateway Lab, part of an investment of 279 million pounds Sterling, was pending, “as we expect more clarity in the British environment on the life sciences”.

The largest British medication manufacturer, Astrazeneca, who was at the forefront of government efforts to make the covid vaccines available during the pandemic, has already disconnected on the expansion of 450 million pounds sterling on his vaccination site in Speke in Liverpool in February after failing to accept a set of state support.

Paul Paul Naish, the market manager of the French pharmaceutical group of Sanofi, said that substantial investments were now pending. “It is an intolerable situation for too much [patients] In this country and that is why the government must work with the sector, “he said.

The manufacturer of Swiss drugs Novartis also has future investments in British manufacturing or research, it is heard. Over the past 16 years, he has reduced his operations in the United Kingdom on seven sites and more than 4,000 employees to a site in London by staying 1,200 employees.

Meanwhile, Biontech in Germany said that its 1 billion pound sterling partnership over 10 years with the British government was aimed at accelerating the trials of cancer drugs, has remained on the right track. Several hundred patients have been treated with immunotherapy of experimental cancer thanks to collaboration, and new research centers are planned in London and Cambridge.

American biotechnology Moderna, known for its cocvid vaccine, has opened a new vaccine manufacturing site in Harwell, Oxfordshire in May.

Investments, crimes and closings of rebuilding sites in the United Kingdom

September Astrazeneca pauses 200 million pounds of research sterling in Cambridge (1,000 jobs)

September Merck SRAPS Research Center of 1 billion pounds sterling (125 jobs)

September Eli Lilly Pause London Gateway Lab, which is part of 279 million pounds of investment sterling

2025-26 Haleon Closing Maidenhead Site (435 jobs)

July Indivior: Based in Slough, struck off from the London Stock Exchange (LSE)

July Verona Pharma: based in London, sold in MSD after having struck LSE in 2020

July Adaptimmune Therapeutics sells four cell therapy active ingredients to US Worldmedds and reduces British workforce by 62%

June GSK closes the Ulverson factory (100 jobs) and cuts to the Château de Barnard in October (200 jobs)

FEBRUARY Astrazeneca SRAPS 450 million investment in Speke, Liverpool

January RESCHLER BIOPHARMA Farm the Stevenage site (30 jobs)

2024 Sanofi reduced his Kymab laboratories to Cambridge (50 jobs)

2023 Recipham closes the Queenborough site on the island of Sheppey (150 jobs)

2022 Novartis sells a Grimsby site (200+ jobs)